Healthcare / Medical DevicesNasdaqCM
$1.37
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF n/d · quality 50.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
11/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
8/100
SEC 0%
Sin guardar todavía.
Market Cap
$14M
P/E
N/A
•EV/EBITDA
N/A
•ROE
19447.7%
↑Gross Margin
29.6%
↓Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2024–2025 · 1 años de histórico normalizado
Revenue CAGR
+16.7%
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.0M · net income $-3.7M · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 |
|---|---|---|---|
| Income Statement | |||
| Revenue | $2.0M | $2.0M | $1.8M |
| Net Income | $-3.7M | $-3.7M | $-5.6M |
| EBITDA | $-3.3M | $-3.3M | $-5.6M |
| EPS | -0.76 | -0.76 | -1.16 |
| Gross Margin | 29.6% | 29.6% | 20.6% |
| Operating Margin | -162.9% | -162.9% | -324.0% |
| Net Margin | -182.8% | -182.8% | -316.8% |
| Returns | |||
| ROE | 19447.7% | 19447.7% | -368.8% |
| Growth & Yield | |||
| Revenue Growth | 16.7% | 16.7% | — |
| EPS Growth | 34.5% | 34.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.